JPH041728B2 - - Google Patents

Info

Publication number
JPH041728B2
JPH041728B2 JP62092947A JP9294787A JPH041728B2 JP H041728 B2 JPH041728 B2 JP H041728B2 JP 62092947 A JP62092947 A JP 62092947A JP 9294787 A JP9294787 A JP 9294787A JP H041728 B2 JPH041728 B2 JP H041728B2
Authority
JP
Japan
Prior art keywords
adjuvant
oil
purified
antigen
detoxified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP62092947A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6310736A (ja
Inventor
Eru Kantoreru Jon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of JPS6310736A publication Critical patent/JPS6310736A/ja
Publication of JPH041728B2 publication Critical patent/JPH041728B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP62092947A 1986-04-15 1987-04-15 免疫学的アジュバント Granted JPS6310736A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/852,120 US4806352A (en) 1986-04-15 1986-04-15 Immunological lipid emulsion adjuvant
US852120 1986-04-15

Publications (2)

Publication Number Publication Date
JPS6310736A JPS6310736A (ja) 1988-01-18
JPH041728B2 true JPH041728B2 (enEXAMPLES) 1992-01-14

Family

ID=25312542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62092947A Granted JPS6310736A (ja) 1986-04-15 1987-04-15 免疫学的アジュバント

Country Status (9)

Country Link
US (1) US4806352A (enEXAMPLES)
JP (1) JPS6310736A (enEXAMPLES)
AU (1) AU574014B2 (enEXAMPLES)
CA (1) CA1300503C (enEXAMPLES)
DE (1) DE3712767A1 (enEXAMPLES)
ES (1) ES2005166A6 (enEXAMPLES)
FR (2) FR2596990B1 (enEXAMPLES)
GB (1) GB2189141B (enEXAMPLES)
IT (1) IT1205819B (enEXAMPLES)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
JPH0832637B2 (ja) * 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
WO1990003183A1 (en) * 1988-09-23 1990-04-05 University Of Southern California Immunotherapy vaccine for melanoma tumors
FI902821A7 (fi) * 1989-06-12 1990-12-13 Res Foundation For Mental Hygiene Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
JP2647556B2 (ja) 1991-03-19 1997-08-27 サイトアーレクス・コーポレーシヨン 改良された生物学的活性を有するポリオキシプロピレン／ポリオキシエチレン共重合体類
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
DK0580778T3 (da) * 1991-04-19 2000-01-31 Lds Technologies Inc Konvertible mikroemulsionsformuleringer
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
BR9405957A (pt) * 1993-03-23 1995-12-12 Smithkline Beecham Biolog Composições de vacina contendo lipidio A deacilatado 3-0 monofosforil
DK0702563T3 (da) * 1993-05-27 2003-11-10 Entremed Inc Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
AU709262B2 (en) 1995-10-17 1999-08-26 Board Of Regents, The University Of Texas System Insoluble drug delivery
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
ES2201673T3 (es) * 1998-02-11 2004-03-16 Rtp Pharma Corporation Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios.
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CN1245955C (zh) 1998-05-29 2006-03-22 斯凯伊药品加拿大公司 热保护微粒组合物及其最终蒸汽灭菌的方法
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
RU2233654C2 (ru) 1998-11-20 2004-08-10 Ртп Фарма Инк. Диспергируемые стабилизированные фосфолипидом микрочастицы
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
KR20060116041A (ko) 1999-04-09 2006-11-13 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
EP1214059B1 (en) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
MXPA02008748A (es) 2000-03-17 2003-02-24 Upjohn Co Materiales y metodos para vacuna antisalmonella.
AU2001251370A1 (en) 2000-04-06 2001-10-23 Pharmacia And Upjohn Company Antimicrobial methods and materials
AU2001257115B2 (en) 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
WO2002017883A2 (en) 2000-08-31 2002-03-07 Rtp Pharma Inc. Milled particles
CA2423336C (en) * 2000-09-20 2011-03-08 Rtp Pharma Inc. Stabilised fibrate microparticles
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
EP1361867B1 (en) * 2001-02-22 2007-03-21 Jagotec AG Fibrate-statin combinations with reduced fed-fasted effects
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
ES2376492T3 (es) * 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
CN101827613A (zh) 2007-09-27 2010-09-08 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CA2723918C (en) * 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
MX2011006152A (es) 2008-12-09 2011-07-28 Gilead Sciences Inc Moduladores de receptores tipo toll.
WO2011092846A1 (ja) 2010-01-29 2011-08-04 株式会社 ミキモト 装身具用クラスプ
KR102222869B1 (ko) 2010-05-14 2021-03-04 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
WO2012076668A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
US9993565B2 (en) 2011-04-07 2018-06-12 Neovacs Method for treating IFNalpha related conditions
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
US9023367B2 (en) 2012-07-27 2015-05-05 Baxter International Inc. Compositions comprising chimeric OSPA molecules and methods of use thereof
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN107001449A (zh) 2014-10-15 2017-08-01 芝诺锡拉公司 具有降低的免疫原性的组合物
JP7339285B2 (ja) 2018-06-04 2023-09-05 アプロス セラピューティクス， インコーポレイテッド Ｔｌｒ７ペプチドコンジュゲート
JP7728560B2 (ja) 2018-07-02 2025-08-25 アユヴィス リサーチ インク． 新規免疫調節小分子
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
GB202009411D0 (en) 2020-06-19 2020-08-05 Prokarium Ltd Autotransporter systems
CN112807426A (zh) * 2021-01-26 2021-05-18 郭志文 一种基于动物疫苗的聚合物佐剂、制备方法及其应用
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
JP2024536733A (ja) 2021-09-07 2024-10-08 ユニベルシテ デ トゥール コロナウイルス融合タンパク質
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025068401A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 15 variant
WO2025109155A1 (en) 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
CA943459A (en) * 1968-12-16 1974-03-12 Abbott Laboratories Chemically modified endotoxin immunizing agent
FR2160326B1 (enEXAMPLES) * 1971-11-19 1975-02-07 Anvar
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPH077201B2 (ja) * 1985-10-19 1995-01-30 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法

Also Published As

Publication number Publication date
JPS6310736A (ja) 1988-01-18
DE3712767C2 (enEXAMPLES) 1991-06-27
GB2189141B (en) 1990-07-25
FR2596990B1 (fr) 1990-12-07
FR2598622A1 (fr) 1987-11-20
ES2005166A6 (es) 1989-03-01
DE3712767A1 (de) 1987-10-22
IT1205819B (it) 1989-03-31
US4806352A (en) 1989-02-21
AU7156687A (en) 1987-10-22
FR2598622B1 (fr) 1990-05-11
FR2596990A1 (fr) 1987-10-16
CA1300503C (en) 1992-05-12
GB2189141A (en) 1987-10-21
IT8747855A0 (it) 1987-04-15
GB8709023D0 (en) 1987-05-20
AU574014B2 (en) 1988-06-23

Similar Documents

Publication Publication Date Title
JPH041728B2 (enEXAMPLES)
JP2648305B2 (ja) 多糖類ワクチン
JP3814290B2 (ja) 抗原用のアジュバントおよびその製法ならびに用途
JP5019494B2 (ja) モノホスホリルリピドａの水性免疫アジュバント組成物
JP5075317B2 (ja) 莢膜性多糖類の可溶化および組合せワクチン
JP2515321B2 (ja) ワクチン処方
DE60015084T2 (de) Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
AU710499B2 (en) Adjuvants for viral vaccines
JP2003502388A5 (enEXAMPLES)
JP2002513773A (ja) アジュバント組成物及びその使用法
JP2003502388A (ja) モノホスホリルリピドａの水性免疫学的アジュバント組成物
JPH08325163A (ja) 哺乳動物用ワクチン組成物
US4395394A (en) Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
Harrison et al. Duration of immunity, efficacy and safety in sheep of a recombinant Taenia ovis vaccine formulated with saponin or selected adjuvants
US4310550A (en) Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
Edelman An overview of adjuvant use
Johansson et al. Identification of adjuvants that enhance the therapeutic antibody response to host IgE
AU615016B2 (en) Immunological adjuvent and process for preparing the same, pharmaceutical compositions, and process
CN1226173A (zh) 脱乙酰壳多糖引起的免疫强化
Rhodes Overview: Recent Advances in Vaccine Adjuvants
JP2000504350A (ja) キトサン誘導性免疫強化
JPS63258443A (ja) 新規アルキルアルカノエートおよびその製法

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080114

Year of fee payment: 16